TRex Bio raises $84M to compete in crowded immune drug field

TRex Bio raises $84M to compete in crowded immune drug field

Source: 
BioPharma Dive
snippet: 

The California biotech, which is partnered with Eli Lilly and J&J, plans to use the funds to advance one of its wholly owned drugs for eczema into Phase 1 testing.